Visceral Leishmaniasis Treatment, Italy
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2003-12-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/9/12/03-0178_article |
| _version_ | 1828385516805947392 |
|---|---|
| author | Luigi Gradoni Marina Gramiccia Aldo Scalone |
| author_facet | Luigi Gradoni Marina Gramiccia Aldo Scalone |
| author_sort | Luigi Gradoni |
| collection | DOAJ |
| description | First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure. |
| first_indexed | 2024-12-10T05:21:27Z |
| format | Article |
| id | doaj.art-a9de6dfc345f441093d37ea4a663d9e2 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-10T05:21:27Z |
| publishDate | 2003-12-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-a9de6dfc345f441093d37ea4a663d9e22022-12-22T02:00:47ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592003-12-019121617162010.3201/eid0912.030178Visceral Leishmaniasis Treatment, ItalyLuigi GradoniMarina GramicciaAldo ScaloneFirst-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.https://wwwnc.cdc.gov/eid/article/9/12/03-0178_articleVisceral leishmaniasisdrug treatmentpentavalent antimonyamphotericin BItaly |
| spellingShingle | Luigi Gradoni Marina Gramiccia Aldo Scalone Visceral Leishmaniasis Treatment, Italy Emerging Infectious Diseases Visceral leishmaniasis drug treatment pentavalent antimony amphotericin B Italy |
| title | Visceral Leishmaniasis Treatment, Italy |
| title_full | Visceral Leishmaniasis Treatment, Italy |
| title_fullStr | Visceral Leishmaniasis Treatment, Italy |
| title_full_unstemmed | Visceral Leishmaniasis Treatment, Italy |
| title_short | Visceral Leishmaniasis Treatment, Italy |
| title_sort | visceral leishmaniasis treatment italy |
| topic | Visceral leishmaniasis drug treatment pentavalent antimony amphotericin B Italy |
| url | https://wwwnc.cdc.gov/eid/article/9/12/03-0178_article |
| work_keys_str_mv | AT luigigradoni visceralleishmaniasistreatmentitaly AT marinagramiccia visceralleishmaniasistreatmentitaly AT aldoscalone visceralleishmaniasistreatmentitaly |